Serial Number
79383436
Owner
JEIL PHARMACEUTICAL CO., LTDAttorney
John M. KimFiling Date
Sep 14, 2023
JAQBO Trademark
Serial Number: 79383436 • Registration: 7592609
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
John M. Kim IPLA, LLP
4445 Eastgate Mall
Suite 200
San Diego, CA 92121
United States
Trademark Details
Filing Date
September 14, 2023
Registration Date
December 10, 2024
Published for Opposition
October 8, 2024
Goods & Services
Veterinary pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitor, namely, medicines for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; medicines for the prevention and treatment of gastrointestinal diseases; medicines for the treatment of gastrointestinal diseases; medicines for human purposes, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; ethical medicinal preparations, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection